ROCKVILLE, Md. — May 13, 2026 — Bora Pharmaceuticals, a Taiwan-based contract development and manufacturing organization (CDMO), has entered into an agreement to acquire MacroGenics’ biologics manufacturing facility and related warehouse operations in Rockville, Maryland, for $122.5 million upfront, with the potential for an additional $5 million tied to future operational milestones.
The transaction expands Bora’s U.S. manufacturing footprint and adds biologics production capabilities through a facility currently supporting clinical and commercial-stage oncology programs.
According to reports, approximately 140 MacroGenics employees are expected to transition to Bora as part of the acquisition. The Rockville site includes approximately 11,000 liters of biologics manufacturing capacity and currently supports production activities for both internal and external programs.
MacroGenics has used the facility to manufacture drug substances for the majority of its clinical pipeline, as well as for Margenza and Zynyz, oncology therapies commercialized by partners TerSera and Incyte, respectively.
As part of the transaction, MacroGenics plans to establish a manufacturing and supply agreement with Bora to continue supporting process development and drug substance manufacturing for its internal therapeutic pipeline.
The company said the deal is expected to provide nondilutive capital to help extend its financial runway while allowing continued access to manufacturing capabilities without maintaining direct ownership of the facility.
For Bora, the acquisition continues a broader growth strategy built through strategic manufacturing acquisitions. Since 2013, the company has expanded its global CDMO network through acquisitions of facilities from Eisai, Impax Laboratories, GlaxoSmithKline (GSK), Eden Biologics, and Upsher-Smith Laboratories, strengthening its capabilities across both small molecule and biologics manufacturing while expanding its presence in the United States.
The Rockville acquisition also reflects continued industry demand for domestic biomanufacturing infrastructure and increased investment in U.S.-based CDMO capacity, particularly in biologics and oncology manufacturing.
The transaction is expected to close subject to customary closing conditions and regulatory approvals.
